Journal
DEPRESSION AND ANXIETY
Volume 36, Issue 3, Pages 235-243Publisher
WILEY
DOI: 10.1002/da.22875
Keywords
active placebo; anxious depression; ketamine; major depressive disorder; midazolam; treatment-resistant depression
Categories
Funding
- National Institute of Mental Health
Ask authors/readers for more resources
ObjectiveTo examine the effect of high baseline anxiety on response to ketamine versus midazolam (active placebo) in treatment-resistant depression (TRD). MethodsIn a multisite, double-blind, placebo-controlled trial, 99 subjects with TRD were randomized to one of five arms: a single dose of intravenous ketamine 0.1, 0.2, 0.5, 1.0mg/kg, or midazolam 0.045mg/kg. The primary outcome measure was change in the six-item Hamilton Rating Scale for Depression (HAMD6). A linear mixed effects model was used to examine the effect of anxious depression baseline status (defined by a Hamilton Depression Rating Scale Anxiety-Somatization score 7) on response to ketamine versus midazolam at 1 and 3 days postinfusion. ResultsN=45 subjects had anxious TRD, compared to N=54 subjects without high anxiety at baseline. No statistically significant interaction effect was found between treatment group assignment (combined ketamine treatment groups versus midazolam) and anxious/nonanxious status on HAMD6 score at either days 1 or 3 postinfusion (Day 1: F(1, 84)=0.02, P=0.88; Day 3: F(1, 82)=0.12, P=0.73). ConclusionIn contrast with what is observed with traditional antidepressants, response to ketamine may be similar in both anxious and nonanxious TRD subjects. These pilot results suggest the potential utility of ketamine in the treatment of anxious TRD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available